STOCK TITAN
  1. Home
  2. News
  3. ILMN

Illumina Inc - ILMN STOCK NEWS

Welcome to our dedicated news page for Illumina (Ticker: ILMN), a resource for investors and traders seeking the latest updates and insights on Illumina.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Illumina's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Illumina's position in the market.

News
Illumina Named to the Dow Jones Sustainability Indices for the Fifth Consecutive Year
Rhea-AI Summary
Illumina (ILMN) has been named to the Dow Jones Sustainability World Index and the North America Index for 2023 in the Life Sciences Tools & Services Industry. This is the fifth consecutive year the company has been named to the prestigious list and the fourth year that it has led with the highest score in the Life Sciences Tools & Services Sector industry in North America. The Dow Jones Sustainability Index (DJSI) is based on the S&P Global Corporate Sustainability Assessment (CSA) annual evaluation of companies' sustainability practices. The DJSI represents the top 10% of each industry in the DJSI World Index and the top 20% for the DJSI North America Index. Illumina's commitment to deepening its impact on human health and sustainability is evident through this recognition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Illumina submits Form 10 to the Securities and Exchange Commission
Rhea-AI Summary
Illumina, Inc. (NASDAQ: ILMN) has submitted a draft registration statement on Form 10 for the potential divestiture of GRAIL to the U.S. Securities and Exchange Commission. The company received an order from the European Commission (EC) directing the divestiture of GRAIL. Illumina is exploring divestiture options to achieve maximum value for shareholders and the best outcome for GRAIL.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.16%
Tags
none
-
News
Validation Data on a Novel Prognostic Test Developed by GRAIL in Stage I Lung Cancer Presented at North America Conference on Lung Cancer
Rhea-AI Summary
GRAIL, LLC (AZN) presented validation results for a plasma-based targeted methylation assay for early-stage lung cancer at the North America Conference on Lung Cancer 2023. The assay demonstrated the potential to identify high-risk patients who might benefit from additional treatment. The clinical validation studies showed that the presence of ctDNA correlated with an inferior two-year recurrence-free survival, and ctDNA positivity was associated with higher rates of mediastinal nodal upstaging at resection, PD-L1 positivity, and grade 3 histology. Analytical studies also demonstrated high analytical specificity, accuracy to detect signal at low ctDNA input, and a robust LoD95 of tumor methylated fraction. GRAIL has a strategic collaboration with AstraZeneca to develop and commercialize companion diagnostic assays for use with AstraZeneca’s therapies, and the company has announced the availability of its state-of-the-art research use only methylation solution for custom oncology applications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.13%
Tags
none
News
Video: Merging Discovery With Clinical Care at Ontario Institute for Cancer Research
Rhea-AI Summary
Illumina (ILMN) is partnering with the Ontario Institute for Cancer Research (OICR) to push the boundaries of precision oncology. OICR aims to bring researchers, clinicians, and institutes together to solve cancer problems through precision medicine. The institute features a fully equipped genomic sequencing facility and is working to deliver clinically relevant data in a timely manner. OICR's partner organizations, such as Princess Margaret Cancer Centre, rely on genomic sequencing data to guide treatment and clinical trials. The collaboration with Illumina has led to faster genomic sequencing capabilities, potentially changing the economics of genomic sequencing and opening new applications for precision oncology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.37%
Tags
acquisition
-
News
GRAIL To Initiate REACH Study To Evaluate Clinical Impact Of GalleriⓇ Multi-Cancer Early Detection (MCED) Test Among The Medicare Population
Rhea-AI Summary
GRAIL, LLC: Announces the initiation of Real-world Evidence to Advance Multi-Cancer Early Detection Health Equity (REACH/Galleri-Medicare study) following FDA and CMS approvals. The study aims to assess the clinical impact of Galleri® multi-cancer early detection test among Medicare beneficiaries, with a focus on under-represented groups. Medicare will cover the costs of Galleri and related items and services for study participants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.49%
Tags
none
-
News
Illumina To Webcast Upcoming Investor Conferences
Rhea-AI Summary
Illumina, Inc. (NASDAQ: ILMN) executives to speak at investor conferences. Webcasts accessible through Investor Info section of Illumina's website. Replays available for at least 30 days after each event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.75%
Tags
conferences
News
Illumina launches Global Health Access Initiative to support acceleration of pathogen sequencing in low- and middle-income countries
Rhea-AI Summary
Illumina Inc. (NASDAQ: ILMN) Launches Global Health Access Initiative to Address Barriers to Genomic Sequencing in Low- and Middle-Income Countries (LMICs)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.67%
Tags
none
-
News
Illumina Reports Financial Results for Third Quarter of Fiscal Year 2023
Rhea-AI Summary
Illumina, Inc. (Nasdaq: ILMN) announced the appointment of new CEO Jacob Thaysen, Ph.D., and provided financial results for Q3 2023, including revenue of $1.12 billion, a flat year-over-year comparison. The company also expects a decrease in fiscal year 2023 revenue and diluted earnings per share. Illumina remains committed to divesting GRAIL and is focused on driving placements of the NovaSeq X instruments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.05%
Tags
earnings
-
News
Veracyte Announces In Vitro Diagnostic Agreement with Illumina to Broaden Availability of Its Tests for Patients Globally
Rhea-AI Summary
Veracyte, Inc. (Nasdaq: VCYT) announces multi-year agreement with Illumina, Inc. (Nasdaq: ILMN) to develop high-performing molecular tests for decentralized in vitro diagnostic (IVD) tests on Illumina’s NextSeq 550Dx NGS instrument, part of Veracyte’s expanded IVD approach. The first tests to be developed are Prosigna Breast Cancer Assay and Percepta Nasal Swab test, aimed at improving diagnostic and treatment decisions for breast cancer and lung nodules. Illumina's NextSeq 550Dx instrument offers validated mid-throughput platform with regulatory approvals in over 60 countries, broadening market access and enabling faster turnaround times for patients and physicians.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.32%
Tags
none
News
The Race Results Are in - And So Is the Marine Genomic Data
Rhea-AI Summary
Environmental DNA collection kits developed by the molecular surveillance team at New Zealand's Cawthron Institute were used by a sailor during a solo race, showcasing their potential to provide near-real-time biological data about marine communities and support environmental sustainability efforts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.47%
Tags
none
Stock ILMN logo
Illumina Inc

Nasdaq:ILMN

ILMN Rankings

#523 Ranked by Market Cap
#4729 Ranked by Stock Gains
N/A Ranked by Dividends

ILMN Stock Data

20.24B
158.41M
0.24%
94.5%
3.32%
Analytical Laboratory Instrument Manufacturing
Manufacturing
Link
US
San Diego

About ILMN

at illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. these studies will help make the realization of personalized medicine possible. with such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. as a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. illumina’s innovative, array-based solutions for dna, rna, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.